Legend Biotech Adds Six CAR-T and Immunology Pioneers to Scientific Advisory Board
LEGN•Legend Biotech has engaged six leading cell therapy and immunology experts, including pioneers in CAR-T therapies and autoimmune immunotherapies, to guide its next-generation pipeline development. The advisors will contribute strategic input across translational research, clinical development and manufacturing to expand the company’s end-to-end cell therapy portfolio.
1. Appointment of Scientific Advisory Board
Legend Biotech has appointed six distinguished advisors: Renier Brentjens (CAR-T cell therapies), Carl June (cellular immunotherapies), Spencer Fisk (manufacturing readiness), Maximilian F. Konig (precision immunotherapies), Anthony Polverino (oncology R&D) and Georg Schett (autoimmune CAR-T applications).
2. Strategic Guidance for Pipeline Expansion
These advisors will guide pipeline expansion by providing insights on translational science, clinical trial design, manufacturing processes and identification of high-unmet-need areas to support the development of a diversified, end-to-end cell therapy portfolio.
